Role of biosimilar introduction on insulin glargine prices: a retrospective analysis in 28 European countries
Objective Quantify insulin glargine prices following the market introduction of biosimilars. Examine price levels and price changes for originator and biosimilars, by country.Methods Retrospective quantitative analysis using insulin glargine pricing data, both of the originator product and its biosi...
Saved in:
| Main Authors: | David Beran, Margaret Ewen, Mario Raviglione, Tido von Schoen-Angerer, Davide Morolla |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMJ Publishing Group
2025-01-01
|
| Series: | BMJ Open |
| Online Access: | https://bmjopen.bmj.com/content/15/1/e090484.full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Insulin Glargine Biosimilar Prescribing and Cost Trends in the United Kingdom’s Primary Care from 2020 to 2024
by: Murtada Alsaif, et al.
Published: (2025-06-01) -
On the safety of insulin Glargine
by: Ivan Ivanovich Dedov, et al.
Published: (2009-09-01) -
Insulin price components: case studies in six low/middle-income countries
by: David Beran, et al.
Published: (2019-10-01) -
Insulin prices, availability and affordability in 13 low-income and middle-income countries
by: David Beran, et al.
Published: (2019-06-01) -
Lantus (Insulin Glargin): new insulin on Russian market
by: Editorial team Diabetes Mellitus
Published: (2003-03-01)